Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer

Francesco Chierigo MD1,2 | Marco Borghesi MD, PhD1 | Christoph Würnschimmel MD2,3 | Rocco S. Flammia MD2,4 | Benedikt Horlemann MD2 | Gabriele Sorce MD2,5 | Benedikt Hoeh MD2,6 | Zhe Tian MSc2 | Fred Saad MD2 | Markus Graefen MD3 | Michele Gallucci MD4 | Alberto Briganti MD, PhD5 | Francesco Montorsi MD, PhD5 | Felix K. H. Chun MD6 | Shahrokh F. Shariat MD7,8,9,10,11,12 | Guglielmo Mantica MD1 | Nazareno Suardi MD1 | Carlo Terrone MD1 | Pierre I. Karakiewicz MD2

1Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy
2Department of Urology, Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
3Department of Urology, Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
4Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy
5Division of Experimental Oncology, Department of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
6Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
7Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
8Department of Urology, Weill Cornell Medical College, New York, New York, USA
9Department of Urology, University of Texas Southwestern, Dallas, Texas, USA
10Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
11Department of Urology, Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
12Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan

Correspondence
Francesco Chierigo, MD. Department of Urology, Policlinico San Martino Hospital, University of Genova, Largo Rosanna Benzi 10, Genova 16132, Italy.
Email: francesco.chierigo@gmail.com

Disclosures: Francesco Chierigo and Marco Borghesi contributed equally to the work and should be considered as co-first authors.

Abstract

Aim: To compare overall mortality (OM), cancer-specific mortality (CSM), and other cause mortality (OCM) rates between radical prostatectomy (RP) versus radiotherapy (RT) in clinical node-positive (cN1) prostate cancer (PCa).

Materials and Methods: Within Surveillance, Epidemiology, End Results (SEER) (2004–2016), we identified 4685 cN1 PCa patients, of whom 3589 (76.6%) versus 1096 (24.4%) were treated with RP versus RT. After 1:1 propensity score matching (PSM), Kaplan-Meier plots and Cox regression models tested the effect of RP versus RT on OM, while cumulative incidence plots and competing-risks regression (CRR) models addressed CSM and OCM between RP and RT patients. All analyses were repeated after the inverse probability of treatment weighting.
1 | INTRODUCTION

Clinically lymph-node-positive (cN1) prostate cancer (PCa) represents approximately 12% of PCa cases at initial diagnosis and represents a challenging clinical dilemma with respect to treatment selection between radical prostatectomy (RP) versus radiation therapy (RT). A recent systematic review suggested an advantage in terms of both overall survival (OS) and cancer-specific mortality (CSM) for men with cN1 PCa receiving local treatment. However, to date, only a few studies have compared cancer control outcomes between RP versus RT in cN1 PCa patients. Specifically, Seisen et al. tested the effect of RP (n = 751) versus RT (n = 1236) on OS and found no statistically significant differences (HR = 0.54, 95% CI = 0.19–1.52, p = 0.2). However, they could not address CSM. Similarly, Sarkar et al. did not identify a statistically significant differences in CSM (hazard ratio [HR] = 0.47, 95% confidence interval [CI] = 0.19–1.17; p = 0.1) or OS (HR = 0.88, 95% CI = 0.46–1.70; p = 0.71) between RP (N = 78) versus RT (N = 445).

It is of note that in both studies RP effect trended towards a survival benefit versus RT. Moreover, Jang et al. showed that men clinically node-positive PCa treated initially with RP + adjuvant RT had a lower risk of CSM and improved OS when compared to those men treated with RT + androgen deprivation therapy, but experienced higher rates of erectile dysfunction and urinary incontinence. Based on a limited amount of data examining these two alternative treatment modalities, we initiated a contemporary analysis addressing CSM according to RP versus RT in cN1 PCa patients, after adjustment for OCM, which may mask the effect of local treatment in patients at low CSM but an elevated OCM risk. Our analysis relied on the Surveillance, Epidemiology, and End Results (SEER) database (2004–2016). We hypothesized that no overall mortality (OM), CSM, or OCM differences exist between RP versus RT.

2 | MATERIALS AND METHODS

2.1 | Study population

The SEER database samples 26% of the United States and approximates the United States in terms of demographic composition, as well as cancer incidence. Within SEER database 2004–2016, we identified and included all patients ≥18 years old with histologically confirmed nonmetastatic, cN1 adenocarcinoma of the prostate, diagnosed at biopsy (International Classification of Disease for Oncology [ICD-O-3] code 8140 site code C61.9). Patients with missing vital status, unknown prostate-specific antigen (PSA), unknown clinical T-, N-, M-stages, unknown biopsy Gleason Grade Group (GGG) were excluded. Moreover, we excluded autopsy or death certificate only cases and all patients with treatment other than RP or RT.

CSM was defined as deaths attributable to PCa. Conversely, other cause mortality (OCM) was defined as deaths attributable to other causes than PCa. Follow-up was defined as the time from diagnosis to the end of the study period, loss to follow-up, CSM, or OCM.

2.2 | Statistical analyses

Statistical analyses were based on six steps. First, we tested for differences in OM, CSM, and OCM rates in the unmatched population of RP versus RT. For OM analysis, we relied on multivariable Cox regression models, after adjustment for age, biopsy GGG, clinical T stage, and race. For CSM and OCM analysis, we relied on competing risks regression (Fine-Gray). Second, we matched RT cN1 patients with RP cN1 patients, in a 1:1 fashion, according to age, biopsy Gleason score, clinical T stage, PSA (in 5 ng/ml intervals), and repeated OM, CSM, and OCM analyses. Finally, as previous analyses relied on inverse probability of treatment weighting (IPTW) instead of PSM, we repeated all OM, CSM, and OCM analyses.
analyses in RP versus RT after IPTW (according to a year of diagnosis, age, region, rural versus urban, marital status, socioeconomic status, biopsy GGG, clinical T stage, and PSA). The IPTW is computed by inverting the probability of treatment received. Specifically, it was computed as 1/propensity score for those who received RP, and 1/ (1–propensity score) for RT patients. Applying IPTW in Fine and Gray’s method is not well developed at the R software level. However, according to previously defined methodology, we included the propensity score as an independent variable inside of the regression as a proxy. Specifically, we estimated cumulative incidences and proportional sub-hazards of cancer-specific mortality accounting for other-cause mortality (and vice versa) in the IPTW-adjusted groups. Equality of the cumulative incidence curves was tested by a modified log-rank test. For all statistical analyses, R software environment for statistical computing and graphics (version 3.4.3) was used. All tests were two-sided with a level of significance set at p < 0.05.

# RESULTS

## Study population characteristics

We identified 4685 cN1 PCa patients. Of those, 3589 (76.6%) underwent RP versus 1096 (24.4%) RT. In general, RT patients were older, harbored higher PSA values, higher clinical T stage, and higher biopsy GGG (Table 1 and Figure 1). Specifically, median (interquartile ranges [IQR]) age was 63 (57–67) in RP-treated patients versus 67 (61–73) in those treated with RT. Median PSA was 10.1 (6.3–18.7) versus 22 (10.1–54) ng/ml for RP versus RT, respectively. Moreover, clinical T stage (cT1, cT2, cT3, cT4, and cTx stages were, respectively, 44.7% versus 23.4%; 41.4% versus 32%; 11.5% versus 33.5%; 1.3% versus 10.1%; and 1% versus 0.9% in RP versus RT. Finally, rates of GGG 1, GGG 2, GGG 3, GGG 4, GGG 5, and unknown GGG between RP versus RT were, respectively, 4.5% versus 3.6%; 19.4% versus 8.7%; 21.6% versus 11.8%; 20.9% versus 27%; 29.1% versus 44.3%; and 4.5% versus 4.7%.

## Survival analyses (OM, CSM, OCM) before propensity score matching (PSM)

Before PSM, in the overall cohort of cN1 patients (N = 4685), 5-year OM rates were 11.7% versus 26.8% (p < 0.001) for, respectively, RP versus RT (Figure 2A), which translated into an HR of 0.58, 95% CI = 0.49–0.70, p < 0.001, after multivariable adjustment for PSA, biopsy GGG, cT stage, age, and race (Table 2).

Moreover, cumulative incidence plot-derived 5-year CSM rates were 7.1% versus 17.9% (p < 0.001) for, respectively, RP versus RT (Figure 2B), which translated into an HR of 0.62 (95% CI = 0.49–0.78, p < 0.001), after multivariable adjustment for PSA, biopsy GGG, cT stage, age, and race (Table 2).

Finally, cumulative incidence plot-derived 5-year OCM rates were 4.6% versus 8.9% (p < 0.001) for, respectively, RP versus RT (Figure 2B), which translated into an HR of 0.64 (95% CI = 0.48–0.84, p < 0.001), after multivariable adjustment for PSA, biopsy GGG, cT stage, age, and race (Table 2).

## PSM (1:1)

To address population differences, 1:1 PSM according to age, biopsy GGG, cT stage, and PSA (at 5 ng/ml intervals) was applied to the entire cohort of patients (N = 4685), of whom 3589 underwent RP versus 1096 RT. PSM resulted in two equally sized groups of 894 RP versus 894 RT patients (Table S1 and Figure S1).

## Survival analyses (OM, CSM, OCM) after PSM

Kaplan–Meier plot (Figure 3A) depicting OM at 5 years of follow-up revealed 15.4% versus 25% rates for, respectively, RP versus RT.
(\(p < 0.001\)). The latter translated into a multivariate Cox regression hazard ratio (HR) of 0.63 (95% CI = 0.52–0.78, \(p < 0.001\)) favoring RP, after adjustment for PSA, cT stage, biopsy GGG, age, and race (Table 3).

Cumulative incidence plots (Figure 3B) depicting CSM at 5 years of follow-up revealed 10.4% versus 16.2% rates for respectively RP vs. RT \((p < 0.01)\). The latter translated into a multivariate competing-risks HR of 0.66 (95% CI = 0.52–0.86, \(p < 0.001\)) favoring RP, after adjustment for OCM and additional multivariable adjustment for PSA, cT stage, biopsy GGG, age, and race (Table 3).

Cumulative incidence plots (Figure 3B) depicting OCM at 5 years of follow-up revealed rates were 5.0% versus 8.2% rates for, respectively, RP vs. RT \((p = 0.01)\). The latter translated into a multivariate competing-risks HR of 0.71 (95% CI = 0.5–1.0, \(p = 0.05\)) favoring RP, after adjustment for CSM and additional multivariable adjustment for PSA, cT stage, biopsy GGG, age, and race (Table 3).

3.5 | Survival analyses (OM, CSM, OCM) after IPTW

IPTW adjusted for differences according to the year of diagnosis, age, region of residence, rural versus urban, marital status, socioeconomic status, biopsy GGG, clinical T stage, and PSA, which might have influenced assignment to either RP or RT.

After IPTW (Figure S2), Kaplan Meier plots depicting OM (Figure 4A), and cumulative incidence plots depicting CSM and OCM (Figure 4B) at 5 years of follow-up revealed rates of 13% versus 22.1%, 8.4% versus 15.3%, and 4.6% versus 6.8%, respectively, for RP versus RT (all \(p < 0.001\)). After IPTW, multivariable Cox regression model for OM (Table 4) yielded HR of 0.55 (95% CI = 0.46–0.66, \(p < 0.001\)) favoring RP, while multivariable competing risks regression models yielded HRs of 0.49 (0.34–0.70, \(p < 0.001\)) and 0.54 (0.36–0.79, \(p < 0.001\)) for, respectively, CSM and OCM, all favoring RP, after further adjustment for race (Table 4).
4 | DISCUSSION

We hypothesized that no differences exist in CSM and OCM rates of cN1 patients treated with RP versus RT. We tested this hypothesis within a large, contemporary, population-based sample of cN1 patients treated with RT versus RP. Our study resulted in several noteworthy observations.

First, we observed very important differences in age, PSA, clinical stage, and biopsy GS characteristics of RP patients, relative to their RT counterparts. Specifically, RT patients were older and had a more aggressive disease. These findings are in accordance with those of Seisen et al., who also reported older age, and higher PSA, clinical T stages, and biopsy Gleason scores in cN1 patients treated with RT versus RP. Based on these very
important differences, meaningful comparisons without the strictest statistical adjustment may potentially result in severely biased results. In consequence, we applied PSM and additional multivariable adjustments to control for such differences. The use of PSM reduced the RT population from 1096 to 894 patients and, even more importantly, the RP population from 3589 to 894 patients. This attrition emphasizes the existence of very strong case-mix differences between RP versus RT. These differences might be too pronounced for correction with multivariable adjustment methods alone; instead, they should ideally be addressed with PSM or IPTW, as was done in the current analysis, as well as in that of Seisen et al.⁴ and Jang et al.,³ but not in that of Sarkar et al.⁵ The degree of attrition of assessable patients after matching (1096 to 894 for RT versus 3589 to 894 for RP) also emphasizes the lack of comparability between a large proportion of RP patient’s versus RT counterparts. Therefore, despite PSM allowing head-to-head comparison between RP- and RT-treated patients, incidence rate estimates after PSM should be interpreted with caution, as the after-matching population is not representative of the real-life scenario. The attrition phenomenon only applies to PSM, but not to IPTW, where instead each original observation is kept within the analytic cohort after adjustment of its weight. In consequence, Seisen et al. who relied on IPTW were able to address a bigger population than that of our propensity score-matched analysis. To ensure comparability, we also applied IPTW.

In the second part of our analyses, we focused on OM, CSM, and OCM differences between RP versus RT cN1 patients before PSM or IPTW. The resulting 5-year OM, CSM, and OCM rates were invariably lower in RP versus RT patients and RP was associated with respective multivariable HRs of HR of 0.58 (p < 0.001), 0.62 (p < 0.001), and 0.64 (p < 0.001). Since such results without PSM or IPTW may be biased, we repeated analyses of OM, CSM, and OCM after PSM as well as IPTW. As IPTW in Fine and Gray’s method is not well developed at the R software level, we included the propensity score as an independent variable inside of the regression as its weight. In consequence, Seisen et al. who relied on IPTW were able to address a bigger population than that of our propensity score-matched analysis. To ensure comparability, we also applied IPTW.

Here, the resulting 5-year OM, CSM, and OCM rates invariably favored RP versus RT patients and RP was invariably associated with protective multivariable HRs (HR for OM, CSM, and OCM 0.63 [p < 0.001], 0.66 [p < 0.001], 0.71 [p = 0.05] after PSM; and 0.55, 0.49, 0.54 [all p < 0.001], after IPTW).

| TABLE 2 | Multivariable Cox and competing risks regression models testing for the differences in OM, CSM, and OCM in between RP versus EBRT, within the Surveillance, Epidemiology and End Results (2004–2016) database in 4685 nonmetastatic clinical node-positive PCa patients |
|-----------------|------------------|------------------|------------------|
|                 | Cox regression   | Competing risks regression |
|                 | OM               | HR (95% CI) p value | CSM              | HR (95% CI) p value | OCM              | HR (95% CI) p value |
| Treatment (RT as ref) | 0.59 (0.42–0.70) | <0.001            | 0.62 (0.49–0.78) | <0.001            | 0.64 (0.48–0.84) | <0.001            |
| Age             | 1.02 (1.01–1.03) | <0.001            | 1.01 (0.99–1.02) | 0.2               | 1.05 (1.03–1.06) | <0.001            |
| Race (Caucasian as ref) |                 |                   |                  |                   |                  |                   |
| African American | 0.88 (0.72–1.10) | 0.3               | 0.86 (0.64–1.15) | 0.31              | 0.99 (0.7–1.39)  | 0.95              |
| Asian           | 0.60 (0.41–0.87) | 0.008             | 0.74 (0.48–1.14) | 0.18              | 0.48 (0.23–0.98) | 0.04              |
| Hispanic        | 0.79 (0.62–1.00) | 0.05              | 0.8 (0.58–1.1)   | 0.16              | 0.83 (0.56–1.23) | 0.35              |
| PSA (ng/ml)     | 1.00 (1.00–1.01) | 0.01              | 1 (1–1.01)       | 0.02              | 1 (1–1.01)       | 0.71              |
| Clinical T stage (cT1 as ref) |                 |                   |                  |                   |                  |                   |
| cT2             | 1.05 (0.90–1.24) | 0.5               | 1.06 (0.86–1.31) | 0.6               | 1.09 (0.85–1.39) | 0.49              |
| cT3             | 0.98 (0.79–1.22) | 0.9               | 1.07 (0.81–1.41) | 0.64              | 0.86 (0.61–1.22) | 0.4               |
| cT4             | 1.61 (1.17–2.21) | 0.004             | 2.06 (1.39–3.05) | <0.001            | 0.79 (0.4–1.56)  | 0.5               |
| cTx             | 0.52 (0.19–1.40) | 0.2               | 0.85 (0.31–2.34) | 0.76              | 0 (0–0)         | <0.001            |
| Biopsy Gleason Grade Group (GGG 1 as ref) |                 |                   |                  |                   |                  |                   |
| GGG 2           | 1.24 (0.79–1.95) | 0.3               | 1.78 (0.79–4.02) | 0.16              | 0.97 (0.56–1.67) | 0.9               |
| GGG 3           | 1.42 (0.91–2.21) | 0.1               | 2.6 (1.18–5.74)  | 0.02              | 0.86 (0.5–1.5)   | 0.6               |
| GGG 4           | 1.66 (1.08–2.56) | 0.02              | 3.56 (1.63–7.75) | <0.001            | 0.77 (0.45–1.32) | 0.35              |
| GGG 5           | 2.79 (1.84–4.24) | <0.001            | 6.08 (2.83–13.07)| <0.001            | 1.09 (0.66–1.82) | 0.73              |
| Unknown GGG     | 2.55 (1.58–4.11) | <0.001            | 5.29 (2.33–12)   | <0.001            | 1.15 (0.61–2.17) | 0.67              |

Abbreviations: CI, confidence interval; CSM, cancer-specific mortality; EBRT, external beam radiotherapy; GGG, Gleason Grade Group; HR, hazard ratio; OCM, other cause mortality; OM, overall mortality; PSA, prostate-specific antigen; RP, radical prostatectomy; RT, radiotherapy.
Taken together, our observations invariably indicate that RP cN1 patients exhibit lower OM, CSM, and OCM rates. This benefit in CSM and OM may originate from better RP cancer control. This can be partly explained by the fact that the use of RT for cN1 PCa could be highly limited by the absence of accurate pathological pelvic staging that only a meticulous lymph node dissection can provide. Therefore, the cyto-reductive or abscopal effect related to the local treatment of the primary tumor might be reduced for RT patients. Finally, the observed OCM benefit is usually interpreted as a selection bias and it is most likely operational in the current analysis to the same extent as in other SEER analyses.

Our findings are novel and add to the results of Seisen et al. who exclusively focused on OM as an endpoint due to the absence of

FIGURE 3  (A) Kaplan–Meier and (B) cumulative incidence plots after 1:1 propensity score matching depicting (A) overall mortality (OM), and (B) cancer-specific mortality (CSM) and other cause mortality (OCM) in RP versus RT in clinical node-positive prostate cancer patients. CI, confidence interval; HR, hazard ratio; RP, radical prostatectomy; RT, radiotherapy [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 3 Multivariable competing risks regression models testing for the differences in CSM and OCM between RP versus EBRT, after 1:1 propensity score matching (according to age, biopsy Gleason score, clinical T stage, PSA) within the Surveillance, Epidemiology and End Results (2004-2016) database in 1788 nonmetastatic clinical node positive PCa patients

|                          | Cox regression | Competing-risks regression |
|--------------------------|----------------|---------------------------|
|                          | HR (95% CI)    | p value                   |
| Treatment (RT as ref)    | 0.63 (0.52–0.78) | <0.001                    |
| Age                      | 1.03 (1.02–1.04) | <0.001                    |
| Race (Caucasian as ref)  |                |                           |
| African American         | 0.98 (0.72–1.34) | 0.9                       |
| Asian                    | 0.75 (0.46–1.21) | 0.2                       |
| Hispanic                 | 0.78 (0.54–1.13) | 0.2                       |
| PSA (ng/ml)              | 1.00 (0.99–1.01) | 0.07                      |
| Clinical T stage (cT1 as ref) |               |                           |
| cT2                      | 0.95 (0.73–1.23) | 0.6                       |
| cT3                      | 0.87 (0.65–1.17) | 0.4                       |
| cT4                      | 1.71 (1.15–2.53) | 0.008                     |
| cTx                      | 0.70 (0.22–2.24) | 0.5                       |
| Biopsy Gleason Grade Group (GGG 1 as ref) |              |                           |
| GGG 2                    | 1.22 (0.65–2.28) | 0.5                       |
| GGG 3                    | 1.32 (0.72–2.42) | 0.4                       |
| GGG 4                    | 1.28 (0.72–2.28) | 0.4                       |
| GGG 5                    | 1.87 (1.08–3.26) | 0.026                     |
| Unknown GGG              | 2.07 (1.08–3.97) | 0.029                     |

Abbreviations: CI, confidence interval; CSM, cancer-specific mortality; EBRT, external beam radiotherapy; GGG, Gleason Grade Group; HR, hazard ratio; OCM, other cause mortality; OM, overall mortality; PSA, prostate-specific antigen; RP, radical prostatectomy; RT, radiotherapy.

CSM and OCM on the National Cancer Database (NCDB). Unlike NCDB, the SEER database allows the assessment of CSM and OCM as separate endpoints. Moreover, the availability of CSM and OCM allows the strictest methodological assessment of CSM after adjustment for potential bias originating from OCM, as well as of OCM after adjustment for potential bias originating from CSM.

To ensure maximal comparability with Seisen et al. methodology, we relied on two different adjustment techniques for population difference: PSM and IPTW, which was specifically used by Seisen et al. Our findings agree with those of Sarkar et al. with respect to multivariable HR that indicated lower CSM and OM, that was of comparable magnitude to our findings. However, the analysis of Sarkar et al. was undermined by an insufficient sample size that yielded insignificant p values. Conversely, our findings, which are based on a much larger sample size, yielded protective HRs with highly significant p values favoring lower OM, CSM, and OCM in cN1 RP patients relative to their RT counterparts.

Several limitations of our study need to be mentioned. First, since SEER is an observational database, data are retrospective. However, this also applies to other institutional studies, which previously addressed RP versus RT in cN1 patients. This limitation should be considered in the context of currently unavailable RCTs comparing RP versus RT in the cN1 PCa population. Second, the SEER database does not include information regarding comorbidities, which could affect treatment assignment. However, we relied on adjustment for OCM, which represents a well-established proxy of significant comorbidities. Unfortunately, only the SEER-Medicare database allows the concomitant use of comorbidities and OCM. However, it only holds a fraction (approximately 30%) of the SEER database population used in the current analyses. In consequence, SEER-Medicare-derived observations may be more precise, but less robust. Additionally, the absence of earlier cancer-control outcomes, such as biochemical recurrence, progression-free survival, or metastatic progression may also be criticized. However, these endpoints are clearly not as definitive and not as established as the ultimate endpoint of CSM. Moreover, it is important to emphasize that even the strictest and most detailed adjustment methods (PSM, IPTW, competing-risks regression [CRR], etc.) cannot fully...
account for potential residual differences between RT and RP-treated patients.17

Finally, the absence of central pathology review, the lack of information on the treatment decision-making process, the type and duration of androgen deprivation, type and dosage of radiation therapy, and subsequent treatment after RP or RT may represent additional limitations.

5 | CONCLUSIONS

After adjustment for baseline PCa clinical characteristics, at competing risk regression analyses, RP was associated with both lower CSM and lower OCM, when compared to RT. In consequence, the potential benefit of RP in cN1 patients should be considered in treatment planning.
TABLE 4  Regression models testing for the differences in OM, CSM, and OCM in between RP versus EBRT, within the Surveillance, Epidemiology and End Results (2004–2016) database in 4685 nonmetastatic clinical node-positive PCa patients

| Treatment (RT as ref) | Cox regression | Competing risks regression | OCM | p value |
|----------------------|----------------|---------------------------|------|---------|
|                      | OM HR (95% CI) | CSM HR (95% CI)           |      |         |
|                      | p value        | p value                   |      |         |
| Race (Caucasian as ref) |               |                           |      |         |
| African American   | 0.55 (0.45–0.66) | 0.49 (0.34–0.70)       | 0.54 (0.36–0.79) | <0.001 |
|                      | <0.001         | <0.001                    | <0.001 |         |
| Asian               | 0.83 (0.62–1.12) | 0.78 (0.59–1.03)       | 0.83 (0.6–1.17) | 0.3    |
|                      | 0.2            | 0.09                      |         |         |
| Hispanic            | 0.84 (0.59–1.21) | 0.79 (0.58–1.08)       | 0.8 (0.54–1.18) | 0.3    |
|                      | 0.9            | 0.1                       |         |         |
| Propensity score    | —              | 0.80 (0.46–1.40)       | 1.04 (0.58–1.89) | 0.9    |
|                      | —              | 0.4                       |         |         |

Note: We relied on Cox regression models after inverse probability of treatment weighting (IPTW) for OM. In the analyses on CMS and OCM, as a proxy of Fine and Gray’s competing risks regression after IPTW, we relied on the use of the propensity score as a covariate of the regression model.

Abbreviations: CI, confidence interval; CSM, cancer-specific mortality; EBRT, external beam radiotherapy; HR, hazard ratio; OCM, other cause mortality; OM, overall mortality; RP, radical prostatectomy; RT, radiotherapy.

ACKNOWLEDGMENTS

Open access funding provided by Universita degli Studi di Genova within the CRUI-CARE Agreement.

CONFLICTS OF INTEREST

The authors declare no conflicts of interests.

AUTHOR CONTRIBUTIONS

Protocol/project development, data collection or management, data analysis, and manuscript writing/editing: Francesco Chierigo; protocol/project development, data collection or management, data analysis, and manuscript writing/editing: Marco Borghesi; protocol/project development and manuscript writing/editing: Christoph Würnschimmel, Rocco Simone Flamminia, Benedikt Horlemann, Gabriele Sorce, and Pierre I. Karakiewicz; data collection or management, and data analysis: Zhe Tian; manuscript writing/editing: Fred Saad, Markus Graefen, Michele Gallucci, Alberto Briganti, Francesco Montorsi, Felix K.H. Chua, Shahrokh F. Shar-iat, Guglielmo Mantica, Nazareno Suardi, and Carlo Terrone.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from SEER. Restrictions apply to the availability of these data, which were used under license for this study.

ORCID

Francesco Chierigo http://orcid.org/0000-0001-7357-0758
Christoph Würnschimmel http://orcid.org/0000-0001-7891-4791
Benedikt Hoeh http://orcid.org/0000-0002-4238-6584

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.21442
2. Ventimiglia E, Seisen T, Abdollah F, et al. A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer. Eur Urol Oncol. 2019;2:294-301. doi:10.1016/j.euo.2019.02.001
3. Jang TL, Patel N, Faena I, et al. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer. 2018;124:4010-4022. doi:10.1002/CNCR.31726
4. Seisen T, Vetterlein MW, Karabon P, et al. Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis. Eur Urol. 2018;73:452-461. doi:10.1016/j.euro.2017.08.011
5. Sarkar RR, Bryant AK, Parsons JK, et al. Association between radical prostatectomy and survival in men with clinically node-positive prostate cancer. Eur Urol Oncol. 2019;2:584-588. doi:10.1016/j.euo.2018.09.015
6. About the SEER Program. n.d. Accessed March 22, 2021. https://seer.cancer.gov/about/
7. Fine J, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509. doi:10.1080/01621459.1999.10474144
8. Vetterlein MW, Seisen T, May M, et al. Effectiveness of adjuvant chemotherapy after radical cystectomy for locally advanced and/or pelvic lymph node-positive muscle-invasive urothelial carcinoma of the bladder: a propensity score-weighted competing risks analysis. Eur Urol Focus. 2018;4:252-259. doi:10.1016/J.EUF.2016.07.001
9. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98-101.
10. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the “pre-metastatic niche”: within bone and beyond. Cancer Metastasis Rev. 2006;25:521-529. doi:10.1007/s10555-006-9306-9
11. Reynders K, Illidge T, Siva S, Chang JY, De Roosacker D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41:503-510. doi:10.1016/j.ctrv.2015.03.011
12. About the National Cancer Database. n.d. Accessed April 20, 2021. https://www.facs.org/quality-programs/cancer/ncdb/about
13. Knipper S, Palumo C, Pecoraro A, et al. Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason score 9-10 at biopsy: a population-based analysis. Urol Oncol Semin Orig Invest. 2020;38:79.e9-79.e14. doi:10.1016/j.urolonc.2019.09.015
14. Knipper S, Pecoraro A, Palumo C, et al. A 25-year period analysis of other-cause mortality in localized prostate cancer. Clin Genitourin Cancer. 2019;17:395-401. doi:10.1016/j.clgc.2019.07.008
15. Bandini M, Preissler F, Nazzani S, et al. The effect of other-cause mortality adjustment on access to alternative treatment modalities for localized prostate cancer among African American Patients. Eur Urol Oncol. 2018;1:215-222. doi:10.1016/j.euo.2018.03.007
16. Brief Description of SEER-Medicare Database. n.d. Accessed April 20, 2021. https://healthcaredelivery.cancer.gov/seermedicare/about/overview/
17. Pearlstein KA, Basak R, Chen RC. Comparative effectiveness of prostate cancer treatment options: limitations of retrospective
analysis of cancer registry data. *Int J Radiat Oncol Biol Phys.* 2019; 103:1053-1057. doi:10.1016/j.ijrobp.2018.08.001

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

---

**How to cite this article:** Chierigo F, Borghesi M, Würnschimmel C, et al. Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer. *The Prostate.* 2022;82:740-750.
doi:10.1002/pros.24317